[When is surgical resection of the primary tumor indicated in metastatic prostate cancer and what is the scientific rationale?]
Similar to other tumour entities, analyses of cancer databases giving hope that patients with advanced prostate cancer with osseous metastases benefit from cytoreductive surgery. Prospective clinical trials are in the process of proving this hypothesis. This review article focuses on molecular genetic pathways and clinical data.
Urologische Klinik, Ruhr-Universität Bochum, Hölkeskampring 42, 44625, Herne, Deutschland. joachim.noldus@rub.de.
J
J
Noldus
D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D019317:Evidence-Based Medicine; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000517:prevention & control; D015995:Prevalence; D011468:Prostatectomy / Q000401:mortality* / Q000706:statistics & numerical data*; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome
Bone metastasis; Cytoreductive treatment; Lymph nodes; Metastases; Prostatectomy, radical